Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Staying fit might cut glaucoma risk

Meeting physical activity guidelines and being physically fit may reduce the risk of developing glaucoma by 40 percent to 50 percent, recent research suggests.

Read More »

Links seen between asthma and ADHD

There may be a strong connection between asthma and attention deficit hyperactivity disorder (ADHD) that makes people with one condition more likely to develop the other one, a recent study suggests.

Read More »

Regeneron and Teva’s Fasinumab Hits Primary and Secondary Endpoints in Late-Stage Sub Study

A late-stage study for fasinumab conducted by Regeneron Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd. hit the mark in assessing patients with chronic pain from osteoarthritis of the knee or hip.

Read More »

Earlier onset of type 1 diabetes linked to greater heart risk, shorter life

The earlier a child is diagnosed with type 1 diabetes, the greater the risk of heart disease and a life shortened by as much as 18 years, a large study suggests.

Read More »

J&J Reports Positive Phase III Data for Two-Drug HIV Combo

The Janssen Pharmaceutical Companies of Johnson & Johnson confirmed top-line data from the Phase III Antiretroviral Therapy as Long-Acting Suppression (ATLAS) trial of the first investigational long-acting injectable two-drug regimen for the treatment of HIV-1.

Read More »

Long-acting injection a shot in the arm for GSK’s HIV business

A long-acting injection developed by GlaxoSmithKline and given once a month proved as effective as standard daily pills for controlling the AIDS virus, lifting prospects for the British drugmaker’s key HIV business.

Read More »

Getting too little sleep may ‘age’ the heart

Adults who sleep too little or too much may have an increased risk of heart attack or stroke, say researchers who argue that the best way to think of the harmful effect is in terms of “excess heart age.”

Read More »

PhRMA Releases Annual Survey, Shows Highest R&D Spending Ever

Among the industry group PhRMA’s findings was that overall R&D spending was at an all-time high in 2017, hitting $71.4 billion, up from $65.5 billion in 2016 and from $29.8 billion in 2001.

Read More »

Realm Phase II Trial Fails to Reach Endpoints

Shares of Realm Therapeutics plunged more than 50 percent after the company’s Phase II atopic dermatitis drug failed to distinguish itself from the control arm in the study.

Read More »

‘Back-and-forth’ conversations with young kids may aid brain development

A new study suggests that how parents talk to children may matter just as much as how much time they spend talking.

Read More »

Gemphire Plunges After Investigational Drug Worsens Liver Fat Levels in Pediatric NAFLD Trial Patients

Shares of Gemphire Therapeutics crashed 73 percent in premarket trading after the company revealed its mid-stage non-alcoholic fatty liver disease treatment for pediatric patients actually worsened the disease in some patients.

Read More »

Bexion Pharmaceuticals Early-Stage Cancer Drug Being Hailed as Game Changer

Bexion Pharmaceuticals and the drugmaker’s investigational cancer treatment BXQ-350 is receiving lots of mainstream media coverage as a potential game changer.

Read More »

Obesity, diabetes in pregnancy may raise kids’ risk of psychiatric disorders

Pregnant women who have both severe obesity and diabetes may be more likely to have children with autism, ADHD and other psychiatric disorders than mothers who do not have either condition during pregnancy, a new study suggests.

Read More »

Experts weigh pros and cons of low-calorie sweetened drinks

Low-calorie sweetened beverages such as diet sodas that use aspartame or stevia may be a good replacement for full-sugar sodas and fruit juices, but researchers are still unsure about their long-term health effects, according to a new American Heart Association Science Advisory.

Read More »

First Year After Launch Special Feature 2018: Don’t look back, someone might be gaining

The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.

Read More »

Bellerophon Late-Stage PAH Study Fails

Bellerophon Therapeutics’ Phase III pulmonary arterial hypertension drug INOpulse failed to meet endpoints following a pre-specified interim analysis from a Data Monitoring Committee.

Read More »

Spark’s Hemophilia A Gene Therapy Significantly Reduced Bleeding in Clinical Trial

An investigational gene therapy treatment for hemophilia A saw a 97 percent response rate after one treatment.

Read More »

Ovid’s Angelman Syndrome Therapy Hits Prespecified Endpoint Phase II Trial, Shares Drop Significantly

Ovid Therapeutics reported that the Phase II STARS trial of OV101 for Angelman Syndrome showed “robust and statistically significant improvement,” but the company’s stock plunged nearly 30 percent in premarket trading.

Read More »

Alzheon Researchers Identify Brain Molecule that Inhibits Formation of Alzheimer’s Proteins

Scientists with Framingham, Mass.-based Alzheon identified a substance in the human brain that inhibits the formation of beta-amyloid (Aβ), the primary driver of Alzheimer’s disease.

Read More »

Diet soft drinks tied to lower odds of colon cancer recurrence

Colon cancer patients who drink one or more servings of artificially sweetened beverages a day have roughly half the risk of their cancer recurring compared to those who drink few or none of these beverages, a U.S. study suggests.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom